Jianshi Technology-B (09877.HK) received a Shareholding of 5.4036 million shares listed in Hong Kong from Trinity Elite I International Limited and its affiliates, valued at approximately 17.4515 million Hong Kong dollars.

On December 12, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on December 12, Trinity Elite I International Limited increased its shareholding in $Kangshengtai Technology-B(09877.HK)$ by 5,403,600 shares of Listed in Hong Kong at an average price of HK$3.2296 per share on December 9, which is worth approximately HK$17.4515 million. After the increase, Trinity Elite I International Limited's latest shareholding number is 30,091,400 shares, with a good position ratio of 7.

Futu NewsDec 12 17:04

Healthcare technology company B(09877.HK) received a total of 2.2442 million shares of H股 shares from Trinity Elite I International Limited and its affiliates, worth approximately 6.0712 million Hong Kong dollars.

Reported on November 6, according to the documents disclosed by the Hong Kong Stock Exchange on November 6, Trinity Elite I International Limited increased its shareholding in Health technology - B (09877.HK) by an average price of HK$2.7053 per share on November 1, acquiring 2.2442 million H shares, worth approximately HK$6.0712 million. After the increase, Trinity Elite I International Limited's latest number of shares held is 23.693 million shares, and the favorable warehouse ratio increased from 6.91% to

Futu NewsNov 6 17:04

The one-year clinical data performed excellently, Health World Technology - B (09877) actively explores overseas markets, accelerating the commercialization potential.

As a core l product highly anticipated by the market, LuX-Valve Plus has many highlights in both market prospects and technical value.

Zhitong FinanceNov 4 08:44

The One-Year Outcome of LuX-Valve Plus TRAVEL II Study Was Officially Released at TCT 2024

Yahoo FinanceNov 1 09:46

Genesystechnology - B (09877.HK): LuX-Valve Plus TRAVEL II one-year clinical follow-up results will be released at the 2024 Catheter Cardiovascular Scientific Conference in Washington, USA.

Galunhui October 31st | Health World Technology-B (09877.HK) announced, recently, the one-year clinical follow-up results of LuX-Valve Plus transvascular tricuspid valve interventional replacement system multi-center clinical trial (TRAVEL II) were released at the Transcatheter Cardiovascular Therapeutics Conference (TCT 2024) in the usa. TRAVEL II is mainly used to evaluate the long-term safety and efficacy of LuX-Valve Plus in patients with severe tricuspid regurgitation. The TRAVEL II clinical trial included a total of 96 patients from 15 centers in china. This time clinical

Gelonghui FinanceOct 31 20:42

Hong Kong stock concept tracking | Medical devices trade-in program attracts institutional attention, clear trend of market recovery.

"Trade-in" is accelerating in the field of medical devices, and various provinces are intensively issuing "feasibility announcements", "project approval announcements" and "tender procurement notices", injecting a dose of "cardiotonic" into the market.

Zhitong FinanceOct 29 09:30